HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

HBIO

Harvard Bioscience, Inc. (NASDAQ)

Healthcare — Medical Instruments & Supplies

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

None 1 analysts
$6.13
+$0.03 (+0.41%)
Target: $6.00 (-2.1%)
Sign in to add HBIO to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$27.29M
P/E Ratio (TTM)-
Forward P/E13.75
EPS (TTM)$-2.15
Dividend Yield-
Profit Margin-11.44%
Revenue Growth-4.70%
ROE-78.65%
Debt/Equity439.20
Recommendation None
Analyst Target$6.00
Analysts1
Indexes NASDAQ

Technical Indicators

RSI (14)46.3
Beta1.51
SMA 20-
SMA 40-
52-Week High$9.40
52-Week Low$3.80
50-Day Avg$6.13
200-Day Avg$5.76
Avg Volume23.8K
Volume13.4K

Performance Analysis

BEARISH

HBIO is flashing more cautionary signals — investors should monitor closely.

~ Trading at 42% of its 52-week range.
~ RSI at 46.3 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
- Revenue declined 4.7% year-over-year.
- Operating at a loss with -11.4% margin.
~ Wall Street consensus is "none" from 1 analysts.
- Average analyst target of $6.00 implies 2.1% downside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:13 UTC

Back to Screener Export Report